Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas

Importance: Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) are approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression >1%. These regimens have not been compared prospectively. Objectives: The primary objective was to compare first-line efficacies of single-agent IO to Chemotherapy-IO in patients with advanced LUADs. Secondary objectives were to explore if clinical, pathologic, and genomic features were associated with differential response to Chemotherapy-IO vs IO. Setting: Multicenter retrospective cohort study. Participants: Patients with advanced LUADs with tumor PD-L1 >1% treated with first-line Chemotherapy-IO or IO. Exposures: Chemotherapy-IO vs IO therapy. Main outcomes: Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: The cohort analyzed included 874 patients who received first-line treatment for PD-L1-positive advanced LUAD without sensitizing EGFR or ALK alterations. Relative to IO, Chemotherapy-IO was associated with improved ORR (44% vs 35%, p=0.005) and PFS in patients with tumor PD-L1>1% (HR 0.75, 95% CI 0.0.61-0.92, p=0.005) or PD-L1>50% (ORR 55% vs 38%, p<0.001; PFS HR 0.74 95%CI 0.56-0.97, p=0.032). Using propensity-adjusted analyses, only never smokers in the PD-L1 >50% subgroup derived a differential survival benefit from Chemotherapy-IO vs IO (p=0.03). Among patients with very high tumor PD-L1 expression (>90%) there were no differences in outcome between treatment groups. No genomic factors conferred differential survival benefit to Chemotherapy-IO vs IO. Conclusions and Relevance: While the addition of chemotherapy to PD-(L)1 blockade increases the probability of initial response, never-smokers with tumor PD-L1 >50% comprise the only population identified that derived an apparent survival benefit with treatment intensification.

[1]  G. Yancopoulos,et al.  Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial , 2022, Nature Medicine.

[2]  U. Dafni,et al.  Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Pazdur,et al.  Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. , 2021 .

[4]  P. Jänne,et al.  Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer. , 2021 .

[5]  Page Widick,et al.  Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy , 2021, JAMA network open.

[6]  D. Carbone,et al.  First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[7]  Chengzhi Zhou,et al.  Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma , 2020, Frontiers in Molecular Biosciences.

[8]  G. Giaccone,et al.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.

[9]  D. Hayes,et al.  Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non–Small Cell Lung Carcinoma , 2020, Molecular Cancer Research.

[10]  M. Ladanyi,et al.  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[12]  David R. Jones,et al.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  N. Schultz,et al.  Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. , 2019, JCO precision oncology.

[14]  S. Digumarthy,et al.  Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[16]  S. Khozin,et al.  Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer , 2019, bioRxiv.

[17]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[18]  A. Abernethy,et al.  Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint , 2018, Health services research.

[19]  Arun Ahuja,et al.  Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer , 2018, Cancer cell.

[20]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[21]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[22]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[23]  S. Digumarthy,et al.  Diminished Ef fi cacy of Programmed Death-(Ligand)1 Inhibition in STK11 - and KEAP1 -Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status , 2022 .